KYMR – kymera therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is now covered by analysts at Stephens. They set an "overweight" rating and a $65.00 price target on the stock.
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Morgan Stanley from $45.00 to $49.00. They now have an "equal weight" rating on the stock.
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target lowered by analysts at UBS Group AG from $80.00 to $74.00. They now have a "buy" rating on the stock.
Form SC 13G/A Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Form SC 13G/A Kymera Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Form SC 13G/A Kymera Therapeutics, Filed by: Avoro Capital Advisors LLC
Form SC 13G Kymera Therapeutics, Filed by: FMR LLC
Form SC 13G/A Kymera Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.